Companies › CHRS
COHERUS ONCOLOGY INC (CHRS)
Institutional ownership, SEC filings and insider activity
Sector: Healthcare & Pharma · SEC CIK 0001512762 · EDGAR filings · Updated 2026-07-27
COHERUS ONCOLOGY INC (CHRS) has reported institutional ownership of 38.3%, with 156 institutional managers holding positions valued at $99.8M per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), triggering event that accelerates or increases a direct financial obligation (8-K Item 2.04).
Filings this week (1)
- 2026-07-27 — SCHEDULE 13G filed
Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.
Latest updates
- 2026-06-15 — Current report (8-K) filed
- 2026-06-09 — Insider transaction reported (Form 4)
- 2026-06-09 — Insider transaction reported (Form 4)
- 2026-06-09 — Insider transaction reported (Form 4)
- 2026-06-09 — Insider transaction reported (Form 4)
Institutional ownership overview
According to SEC 13F filings tracked by Sightfile, COHERUS ONCOLOGY INC has 156 institutional holders and institutional ownership of 38.3%.
Insider activity
Insiders reported 5 transactions (0 buys, 1 sells) across 3 reporting insiders, with a net reported value of −$74.0K.
Data flags from SEC filings
Related companies
ELECTROMED INC (ELMD) · SILENCE THERAPEUTICS PLC (SLN) · ZENTALIS PHARMACEUTICALS INC (ZNTL) · FENNEC PHARMACEUTICALS INC (FENC) · Sol-Gel Technologies Ltd (SLGL) · PEPGEN INC (PEPG)
See full history, cross-references and alerts on SightfileData sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-27.